Recurrent Classical Hodgkin Lymphoma (DBCOND0070972)

Identifiers

Synonyms

Classical Hodgkin lymphoma recurrent / Recurrent Classic Hodgkin Lymphoma / Relapsing classical Hodgkin lymphoma (disorder) / Hodgkin's disease recurrent / Hodgkin's disease NOS recurrent

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06504394	A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Hyaluronidase (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)	Hyaluronidase Pembrolizumab	treatment	2	recruiting
NCT04074746	Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas	AFM-13 Acimtamig Cyclophosphamide Fludarabine	treatment	1 / 2	active_not_recruiting
NCT01896999	Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma	Brentuximab vedotin Ipilimumab Nivolumab	treatment	1 / 2	active_not_recruiting
NCT05162976	CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed	Azacitidine Nivolumab	treatment	1	active_not_recruiting
NCT05711628	A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma	Bendamustine Beta-D-Glucose Brentuximab vedotin Carboplatin Cyclophosphamide Doxorubicin Etoposide Gemcitabine Ifosfamide Pembrolizumab Tetracycline Vinorelbine	treatment	3	withdrawn
NCT05518318	GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)	Zimberelimab	treatment	3	not_yet_recruiting
NCT03150329	Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.	Pembrolizumab Vorinostat	treatment	1	active_not_recruiting
NCT02408861	Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Ipilimumab Nivolumab	treatment	1	recruiting
NCT02595866	Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer	Pembrolizumab	treatment	1	completed
NCT05039073	Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors	Brentuximab vedotin Nivolumab	treatment	2	recruiting
NCT00967369	Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.	Beta-D-Glucose Bortezomib Bortezomib D-mannitol Carboplatin Cyclophosphamide Etoposide Ifosfamide	treatment	2	completed
NCT02164500	JAK-inhibition in Recurrent Classical Hodgkin Lymphoma	Ruxolitinib	treatment	2	completed
NCT03229278	Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma	Nivolumab Pembrolizumab	treatment	1	completed